Valacyclovir News and Research

RSS
Valacyclovir is a substance that is being studied in the prevention of fungal, bacterial, and viral infections in patients undergoing donor stem cell transplantation with cells that are infected with cytomegalovirus. It belongs to the family of drugs called antivirals.
Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Study: No association between first-trimester exposure to antiherpetic antiviral drugs and major birth defects

Study: No association between first-trimester exposure to antiherpetic antiviral drugs and major birth defects

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles

FDA approves Roxane Laboratories' Valacyclovir Hydrochloride Tablets ANDA

FDA approves Roxane Laboratories' Valacyclovir Hydrochloride Tablets ANDA

FDA approves Mylan's ANDA for Valacyclovir Hydrochloride Tablets

FDA approves Mylan's ANDA for Valacyclovir Hydrochloride Tablets

FDA approves Watson Pharmaceuticals' generic version of VALTREX tablets

FDA approves Watson Pharmaceuticals' generic version of VALTREX tablets

Cancer drug, antiviral agent can eradicate active virus infection and tumor: UNC School of Medicine

Cancer drug, antiviral agent can eradicate active virus infection and tumor: UNC School of Medicine

Common drug used to treat Burkitt lymphoma can activate EBV: Study

Common drug used to treat Burkitt lymphoma can activate EBV: Study

Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles

Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

Epiphany Biosciences announces results from its valomaciclovir Phase 2b trial for shingles

Epiphany Biosciences announces results from its valomaciclovir Phase 2b trial for shingles

Inhibitex reports Q2 2009 financials

Inhibitex reports Q2 2009 financials

Topical microbicide protects against genital herpes

Topical microbicide protects against genital herpes

Save money wih generics

Save money wih generics

Researchers highlight distinct subtypes of myalgic encephalomyelitis

Researchers highlight distinct subtypes of myalgic encephalomyelitis

Suppressing herpes virus may reduce infectiousness of HIV

Suppressing herpes virus may reduce infectiousness of HIV

Ranbaxy and GSK agree to settle Valacyclovir U.S. patent case

Ranbaxy and GSK agree to settle Valacyclovir U.S. patent case

Long-term herpes treatment may reduce HIV infectivity

Long-term herpes treatment may reduce HIV infectivity

Herpes treatment could slow HIV progression in people living with both viruses

Herpes treatment could slow HIV progression in people living with both viruses

Call for herpes simplex virus control measures for prevention of HIV transmission

Call for herpes simplex virus control measures for prevention of HIV transmission

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.